Zhang Tongli
University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Handb Exp Pharmacol. 2025;289:165-185. doi: 10.1007/164_2024_740.
In this chapter, the potential integration between quantitative systems pharmacology (QSP) and machine learning (ML) is explored. ML models are in their nature "black boxes", since they make predictions based on data without explicit system definitions, while on the other hand, QSP models are "white boxes" that describe mechanistic biological interactions and investigate the systems properties emerging from such interactions. Despite their differences, both approaches have unique strengths that can be leveraged to form a powerful integrated tool. ML's ability to handle large datasets and make predictions is complemented by QSP's detailed mechanistic insights into drug actions and biological systems. The chapter discusses basic ML techniques and their application in drug development, including supervised and unsupervised learning methods. It also illustrates how combining QSP with ML can facilitate the design of combination therapies against cancer resistance to single therapies. The synergy between these two methodologies shows promise to accelerate the drug development process, making it more efficient and tailored to individual patient needs.
在本章中,我们探讨了定量系统药理学(QSP)与机器学习(ML)之间潜在的整合。机器学习模型本质上是“黑匣子”,因为它们基于数据进行预测,而没有明确的系统定义,而另一方面,定量系统药理学模型是“白匣子”,描述机制性生物相互作用并研究由此类相互作用产生的系统特性。尽管它们存在差异,但这两种方法都有独特的优势,可以利用这些优势形成一个强大的集成工具。机器学习处理大型数据集和进行预测的能力,得到了定量系统药理学对药物作用和生物系统的详细机制性见解的补充。本章讨论了基本的机器学习技术及其在药物开发中的应用,包括监督学习和无监督学习方法。它还说明了将定量系统药理学与机器学习相结合如何能够促进针对癌症对单一疗法耐药性的联合疗法的设计。这两种方法之间的协同作用有望加速药物开发过程,使其更高效且更符合个体患者的需求。